Update On HALIX’s Commercial Manufacture Of COVID-19 Vaccine
Leiden, The Netherlands (01.04.2021) – HALIX B.V. is a contractor of AstraZeneca for large-scale commercial drug substance manufacture of AZD1222, AstraZeneca’s COVID-19 vaccine.
While discussions in the political arena are continuing, HALIX keeps on attracting media attention concerning AstraZeneca’s COVID-19 vaccine and the production of drug substance by HALIX for this vaccine.
Unfortunately, there is a lot of incorrect representation of facts in the media regarding the status of HALIX and its facility. HALIX and its facility have been successfully inspected by both IGJ and AstraZeneca on compliance with GMP, the international quality standards for (bio)pharmaceutical manufacturers. On top of that, the HALIX facility was authorized by the European Medicines Agency for the manufacture of the drug substance for the AstraZeneca vaccine. To achieve this in such a short and challenging period of time is in itself a huge accomplishment on the part of HALIX and the HALIX team.
HALIX is committed to continue its work for the manufacture of the drug substance for the AstraZeneca vaccine, support the vaccine production and combat COVID-19.
Because of our obligations towards AstraZeneca and our employees we cannot specifically respond to every news item or press inquiry. We refer to our press releases, issued on March 29th and 26th 2021.
About HALIX
HALIX B.V. is a biopharmaceutical contract development and manufacturing organization (CDMO) for biologics enabling the treatment and prevention of life threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substance and drug product. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX belongs to the family owned Droege Group AG. More information is available on: www.halix.nl
Contact
Corporate Communications HALIX B.V.
Email: communications@halix.nl